Edmond DE Rothschild Holding S.A. Trims Holdings in Solventum Co. (NYSE:SOLV)

Edmond DE Rothschild Holding S.A. cut its stake in Solventum Co. (NYSE:SOLV) by 2.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,331 shares of the company’s stock after selling 553 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Solventum were worth $1,805,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Modus Advisors LLC bought a new position in shares of Solventum in the fourth quarter worth approximately $25,000. Stonebridge Financial Group LLC bought a new stake in shares of Solventum during the 4th quarter valued at $26,000. Crews Bank & Trust purchased a new stake in Solventum in the fourth quarter worth about $32,000. Synergy Asset Management LLC purchased a new stake in Solventum in the 4th quarter worth approximately $35,000. Finally, Spire Wealth Management bought a new stake in shares of Solventum during the 4th quarter valued at $37,000.

Solventum Price Performance

SOLV opened at $76.29 on Wednesday. The business has a fifty day moving average of $75.60 and a 200 day moving average of $71.97. The stock has a market cap of $13.20 billion and a P/E ratio of 27.74. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92.

Wall Street Analyst Weigh In

A number of analysts have issued reports on SOLV shares. Mizuho lifted their price target on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. Wells Fargo & Company upped their price target on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Bank of America lifted their price objective on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. Piper Sandler increased their price target on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a report on Friday, February 28th. Finally, The Goldman Sachs Group lifted their price target on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.